Navigation Links
Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop

ted in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%) in single-agent VELCADE, diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented at ... a therapy being developed by Hera Therapeutics Inc. combats three ... percent of all cervical cancer. When tested in ... HPV-16, HPV-18 and HPV-11 cells, according to Louise T. ... presented the findings at the Seattle ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... Inc. (NYSE: HSP ), a leading global specialty ... will present at the Morgan Stanley Global Healthcare Conference on ... presentation is scheduled to begin at 8:35 a.m. Eastern time ... all interested parties through a live audiocast accessible via the ...
... Wright Therapy Products, Inc. announced today that ... Executive Officer of the company.  The company, based ... devices targeted for the treatment of lymphedema, venous ... Wright Therapy after holding senior financial and sales ...
Cached Medicine Technology:Industry Leaders Hinson and Friel Join Wright Therapy Products 2
(Date:8/23/2014)... 2014 Dealing with a drug or alcohol ... the addict is a child. Adolescent addiction has been an ... time, but a new helpline is now providing a valuable ... to find a real addiction recovery center. , The Troubled ... impact in the community. By calling (404) 975-2762, parents and ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 Search ... on the first page of search engines and ... SEO Hosting has recently compared many Linux hosting ... and Bluehost are the most recommended Linux hosting ... Australia and Europe to buy high quality Linux ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online Health ... Plans. , According to Zane Benefits, employers are adopting ... the cost of healthcare without reducing coverage for employees. ... can be confusing. , The new guide contains a ... types of ABHPs. It also explains the similarities, ...
(Date:8/22/2014)... 23, 2014 This report studies ... Liquid Handling Systems), Consumables (Tubes), Kits (Isolation, Purification), ... Diagnostics) - Global Forecast to 2018" This market ... is poised to grow at a CAGR of ... million by 2018. , Browse 98 market data ...
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and ... wedding gowns . In addition to this, the company’s ... are provided with low shipping fees. , He ... new wedding gowns. In our online store, there are ... choose from. What’s more, all of them are extremely ...
Breaking Medicine News(10 mins):Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2
... harbor profound misperceptions about the effects ... designed to help them quit, PITTSBURGH, Nov. 13 ... dangers of smoking over the past 40 years, a ... GlaxoSmithKline,Consumer Healthcare, an industry leader in smoking cessation, indicates,major ...
... Disease & Kennel Cough: Serious, But Avoidable; ... Reputable Pet Sitter, BERKELEY, Calif., Nov. 13 With ... reports regarding the highly,contagious and potentially deadly strains of canine ... cough virus -- have many dog,owners worried. So, what,s a ...
... is the only way,to describe the unsolicited testimonial received this month by ... Because of your service we were there within about ... is already home as of yesterday evening. Your service ... never work for her because when she has an ...
... Inc., a subsidiary of Natural Nutrition Inc. ... made another major,breakthrough in the international market ... Panama. InterACTIVE Nutrition brand high energy protein,products ... department in Panama.,This is a significant achievement, ...
... Today; ... in the United States, LYON, France, November 13 ... it has,signed an exclusive global collaboration agreement with Acambis plc, ... help fight against,this serious, life-altering and potentially fatal disease. Scientists,believe ...
... carbohydrates may help stunt the growth of prostate tumors, according ... The study, in mice, suggests that a reduction in insulin ... , This study showed that cutting carbohydrates may slow tumor ... urologist at Duke University Medical Center and lead researcher on ...
Cached Medicine News:Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 2Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 3Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 4Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 5Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 6Health News:Safeguard Your Pet From Seasonal Ailments 2Health News:Safeguard Your Pet From Seasonal Ailments 3Health News:Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service 2Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Panama 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:A low-carb diet may stunt prostate tumor growth 2
... The Estriol (unconjugated) enzyme immunoassay (EIA) test ... in vitro,determination of unconjugated estriol in human ... The Estriol (unconjugated) procedure is an enzyme ... competitive binding. In this procedure, estriol is ...
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... based on the competition principle and the ... in the sample and a fixed amount ... for the,binding sites of a polyclonal Estradiol ... hours incubation the microtiterplate is,washed to stop ...
... the most important androgen secreted into the ... the Leydig cells of the testes; in ... derived from,peripheral conversion of androstenedione, ca. 25% ... the adrenal glands. The Testosterone ELISA KIT ...
Medicine Products: